Medtronic received information via literature regarding short- and long-term outcomes after aortic valve reoperation after stentless bioprosthesis.All data were collected from a single center between 1997 and 2017.The study population included 143 patients (predominantly female, mean age 59 years), all of them were initially implanted with medtronic freestyle bioprosthesis.No serial numbers were provided.Approximately, 9 years post-implant the freestyle valve was replaced with freestyle stentlesss valve in 70 patients due to aortic stenosis, patient-prosthesis mismatch, aortic insufficiency, infective endocarditis with abscess ans structural valve deterioration (svd).Among all patients, 30-day and in-hospital mortality was 1% and 2%, respectively.Multiple manufacturers were noted in the literature.Based on the available information, medtronic product did not cause or contribute these deaths.Among all patients, adverse events included: aortic stenosis, patient-prosthesis mismatch, aortic insufficiency, infective endocarditis with abscess, infection, bleeding, tamponade, atrial fibrillation, complete heart block (chb), permanent pacemaker implantation and structural valve deterioration (svd) including calcification, leaflet fracture.Based on the available information a direct correlation could not be made between medtronic product and the observed adverse events.No additional adverse patient effects or product performance issues were reported.
|